Neurocrine Slides As Ingrezza Serious Cases Count Updated In FDA System By: TalkMarkets November 14, 2018 at 17:50 PM EST In afternoon trading, shares of Neurocrine Biosciences have plunged more than 11% to $88.45. Read More >> Related Stocks: Neurocrine Bioscienc